Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Other Non-Current Liabilities (2010 - 2026)

Talphera (TLPH) posted Other Non-Current Liabilities of $1.7 million for Q2 2026, up 48.57% on a QoQ basis from $1.2 million in Q1 2026, and up 125.69% year-over-year from $759000.0 in Q2 2025.

Analysis

Talphera (TLPH) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends

Talphera has reported Other Non-Current Liabilities for 17 years, with the latest figure at $1.7 million in Q2 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 125.69% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 125.69% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 123.94% from the prior year.
  • Other Non-Current Liabilities was $1.7 million for Q2 2026 at Talphera, up from $1.2 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $84.6 million in Q1 2022, with the low at $759000.0 in Q2 2025.
  • Average Other Non-Current Liabilities over 5 years is $6.6 million, with a median of $1.8 million recorded in 2023.
  • The largest YoY upside for Other Non-Current Liabilities was 46648.62% in 2022 against a maximum downside of 99.04% in 2022.
  • Over 5 years, Other Non-Current Liabilities stood at $7.1 million in 2022, then plunged by 74.95% to $1.8 million in 2023, then slumped by 40.33% to $1.1 million in 2024, then soared by 123.94% to $2.4 million in 2025, then slipped by 27.9% to $1.7 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $1.7 million (Q2 2026), $1.2 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Talphera 92.90 Mn 92.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.71 Mn
Mar 31, 2026 1.15 Mn
Dec 31, 2025 2.38 Mn
Sep 30, 2025 1.85 Mn
Jun 30, 2025 759,000.00
Mar 31, 2025 880,000.00
Dec 31, 2024 1.06 Mn
Sep 30, 2024 2.08 Mn
Jun 30, 2024 2.33 Mn
Mar 31, 2024 2.78 Mn
Dec 31, 2023 1.78 Mn
Sep 30, 2023 1.38 Mn
Jun 30, 2023 3.09 Mn
Mar 31, 2023 1.79 Mn
Dec 31, 2022 7.10 Mn
Sep 30, 2022 827,000.00
Jun 30, 2022 849,000.00
Mar 31, 2022 84.62 Mn
Dec 31, 2021 85.29 Mn
Sep 30, 2021 85.98 Mn